Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia (ALL) and experience higher rates of relapse and treatment toxicity. In recent decades, new therapies have ...

Credit: Getty Images ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.

The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...

A new cell therapy, targeting CD7 on leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment ...

What Is Acute Lymphoblastic Leukemia? Acute lymphoblastic leukemia (ALL) is a type of blood cancer that starts in white blood cells in your bone marrow, the soft inner part of your bones. It develops ...

Nearly one-third of families of children receiving chemotherapy for acute lymphoblastic leukemia (ALL) develop serious ...

The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting ...

In most cases, acute lymphoblastic leukemia (ALL) manifests as a de novo malignancy in previously healthy people. Risk factors for developing ALL include age older than 70 years and genetic disorders, ...

DelveInsight’s, “Acute Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline ...